Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Jul 21, 2017

(R) Cantargia gains approval to initiate the CANFOUR clinical trial of immuno-oncology product candidate CAN04

Jun 26, 2017

(R) Cantargia: Preclinical studies of IL1RAP and CAN04 in solid tumours presented at EACR-AACR-SIC in Florence

Jun 21, 2017

(R) Cantargia receives Notice of Allowance in the US for the CAN04 patent application

Jun 16, 2017

(R) Cantargia AB and Panorama Research Inc. sign agreement to develop an antibody for treatment of autoimmune and inflammatory diseases

Jun 1, 2017

(R) Cantargia obtains patent approval in China for therapy against IL1RAP in acute lymphoblastic leukemia

May 19, 2017

(R) Cantargia strengthens organisation with CFO

May 15, 2017

(R) Cantargia publishes interim report for January-March 2017

May 12, 2017

(R) Cantargia’s application to investigate the antibody product candidate CAN04 in the CANFOUR phase I/IIa clinical trial has been submitted

May 8, 2017

(R) Cantargia’s product candidate CAN04 shows good safety properties in studies performed under GLP

Apr 5, 2017

(R) Cantargia receives an Intention to Grant notice in Europe for its CAN04 product candidate

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye